Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma

Zhang,Wei; Jiao,Li; Zhou,Dao-Bin; Shen,Ti

doi:10.3892/ol_00000128

Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma

Authors:
- Wei Zhang
- Li Jiao
- Dao-Bin Zhou
- Ti Shen
View Affiliations

Affiliations: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000128
Pages: 733-738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this prospective, single-arm study was to test the efficacy and tolerability of autologous stem cell transplantation (auto-SCT) combined with in vivo rituximab purging and post-transplant rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL). This study included 12 DLBCL patients aged 18-65 years with an International Prognostic Index ≥2. The patients received 4-6 cycles of induction therapy consisting of rituximab plus cyclophosphamide, adriamycin, vincristine and prednisone followed by salvage therapy prior to stem cell mobilization. This regimen was followed by rituximab maintenance therapy (375 mg/m2 every three months for two years). Prior to auto-SCT, six patients (50%) achieved complete remission (CR) and six (50%) achieved unconfirmed complete remission (CRu). Three months after transplantation, 11 patients (91.7%) achieved CR and one achieved CRu. After two cycles of rituximab maintenance therapy, all 12 patients achieved CR. Long-term CR was achieved by 10 patients, while two experienced relapse at 14 and 20 months after the end of rituximab maintenance therapy. The median follow-up period was 44 months (range 35-61). Disease-free survival was noted in 10 patients, while two experienced relapse. The three-year overall survival (OS) and progression-free survival (PFS) were 100 and 83%, respectively. Prolonged hypogammaglobulinemia occurred in two patients, although no increase in major infections was observed. Hepatitis B surface antigen was continuously negative in all 12 patients. Our results demonstrated that auto-SCT combined with in vivo rituximab purging and post-transplant rituximab maintenance is safe and effective, and may extend OS and PFS in younger high-risk DLBCL patients.

View Figures

View References

1	The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer. 49:2112–2135. 1982.
2	The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 329:987–994. 1993.
3	Tilly H and Zelenetz A: Treatment of follicular lymphoma: current status. Leuk Lymphoma. 49(Suppl 1): S7–S17. 2008. View Article : Google Scholar
4	Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
5	Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391. 2006. View Article : Google Scholar
6	Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 23:5027–5033. 2005. View Article : Google Scholar : PubMed/NCBI
7	Thieblemont C and Gisselbrecht C: Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep. 11:386–393. 2009. View Article : Google Scholar : PubMed/NCBI
8	Cerny J, Trneny M, Slavickova A, et al: Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. Hematology. 14:187–197. 2009. View Article : Google Scholar : PubMed/NCBI
9	Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 333:1540–1545. 1995.PubMed/NCBI
10	Flohr T, Hess G, Kolbe K, et al: Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant. 29:769–775. 2002. View Article : Google Scholar : PubMed/NCBI
11	Magni M, Di NM, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 96:864–869. 2000.PubMed/NCBI
12	Hicks LK, Woods A, Buckstein R, et al: Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant. 43:701–708. 2009. View Article : Google Scholar : PubMed/NCBI
13	Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 17:12441999.PubMed/NCBI
14	Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol - a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol. 18:3025–3030. 2000.
15	Tarella C, Zanni M, Di NM, et al: Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 21:1802–1811. 2007.
16	Jacquy C, Soree A, Lambert F, et al: A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin’s lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol. 110:631–637. 2000.PubMed/NCBI
17	Goldberg S, Pecora A, Jennis A, et al: Rituximab permits in vivo purging and collection of tumor-free stem cells prior to autologous transplantation for B-cell non-Hodgkin’s lymphoma. Blood. 94:141a1999.
18	Haioun C, Delrau-Larue M, Beaujean F, et al: Efficiency of in vivo purging with rituximab before autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin’s lymphoma (NHL). Blood. 96:384a2000.PubMed/NCBI
19	Salles G, Moullet I, Charlot C, et al: In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients. Blood. 94:141a1999.
20	Mounier N, Gisselbrecht C, Briere J, et al: All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol. 15:1790–1797. 2004.
21	Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 103:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
22	Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI
23	Lim SH, Zhang Y, Wang Z, et al: Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant. 35:207–208. 2005. View Article : Google Scholar : PubMed/NCBI
24	Nishio M, Fujimoto K, Yamamoto S, et al: Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol. 137:349–354. 2007. View Article : Google Scholar
25	Ghielmini M, Schmitz SF, Cogliatti S, et al: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 23:705–711. 2005. View Article : Google Scholar : PubMed/NCBI
26	Cartron G, Blasco H, Paintaud G, Watier H and Le GC: Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 62:43–52. 2007. View Article : Google Scholar : PubMed/NCBI